AHOD2131 - A Randomized, Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and Stage II Classic Hodgkin Lymphoma

Sponsor:

COG

Sponsor Study ID:

AHOD2131

CTO #:

103921

NCT Number:

NCT05675410

Phase:

III

Protocol Type:

Treatment

Age Group:

Both

Disease Sites:

Hodgkin's Lymphoma

Study Objectives:

To compare the PFS of a standard chemotherapy approach versus an IO therapy approach (brentuximab vedotin and nivolumab) in patients with newly diagnosed early stage cHL who have a rapid early response (RER) as determined by PET2 after 2 cycles of doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD) chemotherapy. To compare the PFS of a standard chemotherapy approach versus an IO therapy approach (brentuximab vedotin and nivolumab) plus involved site radiation therapy (ISRT) in patients with newly diagnosed early stage cHL who have a slow early response (SER) as determined by PET2 after 2 cycles of ABVD chemotherapy.

eConsent:

Not available

Study Documents:

Open Study Documents
(MUSC NetID required for document access)